IOL CHEMICALS & PHARMACEUTICALS Q2 FY27 CONCALL: RAISES FY27 REVENUE GROWTH GUIDANCE TO 25%+ FROM 15–20%; MAINTAINS 14–15% EBITDA MARGIN OUTLOOK, TARGETS 15–17% MEDIUM-TERM MARGINS & PLANS ₹500 CR INVESTMENT ACROSS 3 EXPANSION PROJECTS